← Eichor
Study identifier: NCT02843945 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Condition: Pancreatic Cancer  ·  Sponsor: CivaTech Oncology

PhasePhase 1/Phase 2
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

This description comes directly from the study's public registry record.

Talk to the study team

Carra Castagnero  ·  919-314-5515  ·  ccastagnero@civatechoncology.com

Kristy Perez, PhD  ·  9193145515  ·  kperez@civatechoncology.com

Always discuss trial participation with your own doctor first.

Locations (6)

Tampa General HospitalTampa, Florida, United StatesNot Yet Recruiting
Rush University Cancer CenterChicago, Illinois, United StatesCompleted
Advocate Christ Medical CenterOak Lawn, Illinois, United StatesRecruiting
University Medical Center LSUNew Orleans, Louisiana, United StatesCompleted
Fox Chase Cancer CenterPhiladelphia, Pennsylvania, United StatesCompleted
Virginia Commonwealth University Massey Cancer CenterRichmond, Virginia, United StatesCompleted

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02843945